- Home
- MAIA vs KLRS Comparison
MAIA vs KLRS Comparison
Compare MAIA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | KLRS |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 46.0M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | MAIA | KLRS |
|---|---|---|
| Price | $1.53 | $10.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | ★ 1.1M | 58.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $2.14 |
| 52 Week High | $3.19 | $11.90 |
Technical Indicators
Market Signals| Indicator | MAIA | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 51.19 |
| Support Level | $1.20 | $8.08 |
| Resistance Level | $1.69 | $10.64 |
| Average True Range (ATR) | 0.19 | 1.08 |
| MACD | -0.09 | -0.10 |
| Stochastic Oscillator | 10.95 | 55.50 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.